Fresenius Kabi at a glance
Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, we develop products with a focus on oncology and autoimmune diseases.
Fresenius Kabi employs more than 36,000 people worldwide.
With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
In 2017 the company reported sales of more than €6.3 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
|€ in millions||2017||2016||Change|
|Adjusted Net Income3,4||745||675||10%|
1 Before special items
2 Consistent with scope of original guidance: before acquisition-related expenses and expenditures for further development of biosimilars business
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
4 Consistent with scope of original guidance: before acquisition-related expenses, expenditures for further development of biosimilars business and book gain from U.S. tax reform